MedTrace Logo

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration

NCT02725762 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-02-18

No results posted yet for this study

Summary

The purpose of this research study is to determine if photobiomodulation is an effective treatment of Dry Age-Related Macular Degeneration (AMD) and vision loss associated with the disease.

Conditions

  • Age Related Macular Degeneration

Interventions

DEVICE

LT-300 Active (PBM)

DEVICE

LT-300 Inactive (Sham)

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • LumiThera, Inc.

    lead INDUSTRY

Principal Investigators

  • Samuel Markowitz, MD · Private Practice

  • Robert G Devenyi, MD · Ophthalmologist in Chief and Director of Retinal Services, The Donald K. Johnson Eye Center, University Health Network; Professor of Ophthalmology, The University of Toronto; Vitreoretinal Surgery Lead, The Kensington Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02725762 on ClinicalTrials.gov